Insulin-Like Growth Factor-II/Cation-Independent Mannose 6-Phosphate Receptor in Neurodegenerative Diseases
- 19 March 2016
- journal article
- research article
- Published by Springer Nature in Molecular Neurobiology
- Vol. 54 (4) , 2636-2658
Abstract
The insulin-like growth factor II/mannose 6-phosphate (IGF-II/M6P) receptor is a multifunctional single transmembrane glycoprotein. Recent studies have advanced our understanding of the structure, ligand-binding properties, and trafficking of the IGF-II/M6P receptor. This receptor has been implicated in a variety of important cellular processes including growth and development, clearance of IGF-II, proteolytic activation of enzymes, and growth factor precursors, in addition to its well-known role in the delivery of lysosomal enzymes. The IGF-II/M6P receptor, distributed widely in the central nervous system, has additional roles in mediating neurotransmitter release and memory enhancement/consolidation, possibly through activating IGF-II-related intracellular signaling pathways. Recent studies suggest that overexpression of the IGF-II/M6P receptor may have an important role in regulating the levels of transcripts and proteins involved in the development of Alzheimer’s disease (AD)—the prevalent cause of dementia affecting the elderly population in our society. It is reported that IGF-II/M6P receptor overexpression can increase the levels/processing of amyloid precursor protein leading to the generation of β-amyloid peptide, which is associated with degeneration of neurons and subsequent development of AD pathology. Given the significance of the receptor in mediating the transport and functioning of the lysosomal enzymes, it is being considered for therapeutic delivery of enzymes to the lysosomes to treat lysosomal storage disorders. Notwithstanding these results, additional studies are required to validate and fully characterize the function of the IGF-II/M6P receptor in the normal brain and its involvement in various neurodegenerative disorders including AD. It is also critical to understand the interaction between the IGF-II/M6P receptor and lysosomal enzymes in neurodegenerative processes, which may shed some light on developing approaches to detect and prevent neurodegeneration through the dysfunction of the receptor and the endosomal-lysosomal system.Keywords
Funding Information
- Natural Sciences and Engineering Research Council of Canada (#203518)
- Canadian Institutes of Health Research (MOP-84480)
- National Cancer Institute (CA91885)
- National Institute on Aging (R01AG019070)
- Alzheimer Society (Doctoral Award)
- Alberta Innovates - Health Solutions (Graduate Studentship Award)
This publication has 287 references indexed in Scilit:
- The final frontier – crossing the blood‐brain barrierEMBO Molecular Medicine, 2013
- A highly secreted sulphamidase engineered to cross the blood‐brain barrier corrects brain lesions of mice with mucopolysaccharidoses type IIIAEMBO Molecular Medicine, 2013
- Memory enhancement: consolidation, reconsolidation and insulin-like growth factor 2Trends in Neurosciences, 2012
- Endosome maturationThe EMBO Journal, 2011
- A hippocampal insulin‐growth factor 2 pathway regulates the extinction of fear memoriesThe EMBO Journal, 2011
- A Mutation in VPS35, Encoding a Subunit of the Retromer Complex, Causes Late-Onset Parkinson DiseaseThe American Journal of Human Genetics, 2011
- Regulation of apoptosis-associated lysosomal membrane permeabilizationApoptosis, 2010
- Cathepsin D Is the Main Lysosomal Enzyme Involved in the Degradation of α-Synuclein and Generation of Its Carboxy-Terminally Truncated SpeciesBiochemistry, 2008
- Mannose 6-Phosphate Receptor–mediated Transport of Sulfamidase Across the Blood–brain Barrier in the Newborn MouseMolecular Therapy, 2008
- Beta-amyloid toxicity and reversal in embryonic rat septal neuronsNeuroscience Letters, 2007